SSSW(SH:688399) Sou Hu Cai Jing·2025-08-28 03:57Core Viewpoint - The company, Shuoshi Biological (688399.SH), announced voluntary salary reductions for several executives, including a 50% cut for the honorary chairman and the chairman/general manager, as a response to ongoing industry challenges and to demonstrate solidarity during tough times [1][5]. Salary Reduction Details - The honorary chairman, Fang Yongsheng, and the chairman/general manager, Wang Guoqiang, will have their annual salaries reduced by 50% starting from August 15, 2025 [2][3]. - Other executives, including Liu Zhonghua (director and deputy general manager), Hu Yuanyuan (director, deputy general manager, and board secretary), and Zhou Guohui (deputy general manager), will see a 40% salary reduction [2][3]. - The financial director, Meng Yuanyuan, and employee supervisors, Jia Zhaoqiang and Gu Lina, will have their salaries reduced by 10% and 5%, respectively [2][3]. Financial Performance - The company reported a revenue of 176 million yuan in the first half of 2025, a decrease of 1.05% year-on-year, with a net profit of 3.99 million yuan, down 86.35% [6]. - Shuoshi Biological has experienced consecutive years of losses, with revenues of approximately 403 million yuan and 350 million yuan in 2023 and 2024, respectively, and corresponding net profits of -374 million yuan and -2 million yuan [6]. - Despite the decline in performance, the company plans to distribute a cash dividend of 2.85 billion yuan to shareholders, reflecting a commitment to return value to investors [6]. Company Overview - Shuoshi Biological focuses on the research, production, and sales of in vitro diagnostic reagents and related testing instruments, expanding into in vitro testing services to achieve an integrated business model [6].